Newsletters

[University College London (UCL)] Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers.

[Anixa Biosciences, Inc. (PR Newswire)] Anixa Biosciences, Inc. announced updated positive survival observations from its ongoing Phase I clinical trial of liraltagene autoleucel, or lira-cel, a follicle-stimulating hormone receptor-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.

[Science Immunology] Scientists demonstrated that fractalkine-conjugated mRNA lipid nanoparticles can specifically target and deliver mRNA to CX3CR1+ effector CD8 T cells in vitro and in vivo.

[Blood] Using bone marrow samples from multiple myeloma patients, scientists demonstrated a reduction in dysfunctional T cell populations expressing exhaustion markers such as TIGIT, upon treatment with Mezigdomide. They demonstrated the ability of Mezigdomide to enhance survival outcomes from anti-BCMA CAR-T therapy.

[Science Advances] Investigators highlighted the potent antitumor activity of low-dose decitabine-primed CAR T cells (dCAR T) in solid tumor models, a benefit previously confirmed in hematologic malignancies. dCAR T cell infusion in immunocompetent mice led to elimination of mixed tumor masses containing, without the need for prior lymphodepletion.

[Blood] Studies with limited numbers of patients have demonstrated that CAR T-cell products with specificity for >1 antigen are effective in advanced multiple myeloma; however, at this time, none of the dual-targeting CAR T-cell products have been shown to be clearly superior to targeting BCMA alone with ciltacabtagene autoleucel.

[Advanced Science] Using multiple mouse models, scientists found that the impact of CAR-T cells on tumor growth is dose-dependent, capable of promoting, having no effect on, or inhibiting tumor growth. Combining CCL5-knockout CAR-T cells with the CCR5 inhibitor maraviroc significantly enhanced antitumor efficacy.

[Leukemia] Scientists assessed the therapeutic potential of anti-CD117 CAR T cells to target neoplastic mast cells (MCs) in systemic mastocytosis (SM). Anti-CD117-CAR T-cells lysed several SM-related human MC cell lines, MCs differentiated from SM patient-derived iPSCs, and neoplastic bone marrow cells.

[ Bristol Myers Squibb] Bristol Myers Squibb announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic therapy.

[Gut] Researchers elucidated the function of the deubiquitinase JOSD1 in modulating post-translational modification crosstalk and its impact on tumour glycolysis, progression, and immunotherapy response in HCC.

[Nature Metabolism] Investigators showed that biliary epithelial cells safeguard biliary barrier integrity and restrain bile acid-induced fibrogenesis through a cell-intrinsic mechanism involving farnesoid-X-receptor (FXR)–YAP signaling.

[Nature Communications] The authors uncovered a direct interaction between heterochromatin protein 1 (HP1) and nuclear RNA exosome complexes, major RNA decay machineries.